Raymond C. Stevens - Mar 1, 2025 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Jun Yoon, Attorney-in-Fact
Stock symbol: GPCR
Transactions as of: Mar 1, 2025
Transactions value $: -$208,645
Form type: 4
Date filed: 7/3/2025, 05:15 PM
Previous filing: Feb 4, 2025
Next filing: Mar 18, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Stevens Raymond C	CHIEF EXECUTIVE OFFICER, Director	C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO	/s/ Jun Yoon, Attorney-in-Fact	2025-07-03	0001698149

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GPCR	Ordinary Shares	Tax liability	-$98.9K	-12.5K	-1.1%	$7.92	1.12M	Mar 1, 2025	Direct	F1, F2
transaction	GPCR	Ordinary Shares	Award	$0	+89.7K	+8%	$0.00	1.21M	Jul 1, 2025	Direct	F1, F3
transaction	GPCR	Ordinary Shares	Tax liability	-$110K	-16.1K	-1.33%	$6.84	1.19M	Jul 1, 2025	Direct	F1, F2
holding	GPCR	Ordinary Shares						1.55M	Mar 1, 2025	See footnote	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GPCR	American Depositary Shares	Award	$0	+1K		$0.00	1K	May 21, 2025	Ordinary Shares	3K		Direct	F1, F5, F6
holding	GPCR	American Depositary Shares						4K	Mar 1, 2025	Ordinary Shares	12K		See footnote	F1, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
F2	Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.
F3	On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date.
F4	By Raymond Stevens and Vivian Urena-Stevens, as Co-Trustees of the Stevens 2001 Revocable Trust, dated March 28, 2001.
F5	Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.
F6	Voluntary reporting of the acquisition of 1,000 ADSs by the Reporting Person on May 21, 2025 pursuant to the Issuer's Employee Share Purchase Plan.